Takanobu Matsuzaki
Takanobu Matsuzaki has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Hideyuki Saito
Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Kumamoto, Japan
6 shared publications- Hiroshi Nonoguchi
Division of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan
6 shared publications Akinobu Hamada
Kumamoto University Hospital
5 shared publicationsKimio Tomita
Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Kumamoto, Japan
5 shared publications- Hideyuki Saito
Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan
4 shared publications Koji Yokoo
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Oe-honmachi, Kumamoto, Japan
4 shared publications
Latest Publications
- 15 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2871-2878
Minimal Involvement of P-gp and BCRP in Oral Absorption of Ensitrelvir, An Oral SARS-CoV-2 3C-like Protease Inhibitor, in a Non-Clinical Investigation
- 15 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2871-2878
Minimal Involvement of P-gp and BCRP in Oral Absorption of Ensitrelvir, An Oral SARS-CoV-2 3C-like Protease Inhibitor, in a Non-Clinical Investigation
- 11 March 2024
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 56, 101008
Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
- 11 March 2024
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 56, 101008
Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
- 23 September 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (3) , 798-805
Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor
- 23 September 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (3) , 798-805
Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor
- 1 February 2022
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 42, 100426
Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse
- 1 February 2022
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 42, 100426
Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse
- Open Access
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 257, 118048
Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 257, 118048
Open AccessPreventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets
- Open Access
- 1 September 2020
- Published by Elsevier in Neuroscience Letters
- Vol. 735, 135177
The antagonistic activity profile of naloxone in μ-opioid receptor agonist-induced psychological dependence
- 1 September 2020
- Published by Elsevier in Neuroscience Letters
- Vol. 735, 135177
Open AccessThe antagonistic activity profile of naloxone in μ-opioid receptor agonist-induced psychological dependence
- Open Access
- 13 June 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 710-719
The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
Background Baloxavir marboxil (BXM), the oral prodrug of baloxavir acid (BXA), greatly reduces virus titers as well as influenza symptoms of uncomplicated influenza in patients. Objectives To investigate the pharmacokinetic profiles of BXA and its efficacy against influenza A virus infection in ferrets. Methods Ferrets were dosed orally with BXM (10 and 30 mg/kg twice daily for 1 day), oseltamivir phosphate (OSP) (5 mg/kg twice daily for 2 days) or vehicle to measure the antiviral effects of BXM and OSP. The pharmacokinetic parameters of BXA was determined after single oral dosing of BXM. Results The maximum plasma concentrations of BXA were observed at 1.50 and 2.00 hours with the two BXM doses, which then declined with an elimination half‐life of 6.91 and 4.44 hours, respectively. BXM at both doses remained detectable in the plasma in ferrets, which may be due to higher stability in liver microsomes. BXM (10 and 30 mg/kg twice daily) treatment at Day 1 post‐infection (p.i.) reduced virus titers by ≥3 log10 of the 50% tissue culture infective doses by Day 2, which was significantly different compared with vehicle or OSP. Body temperature drops over time were significantly greater with BXM than with vehicle or OSP. Significant reduction in virus titers was also demonstrated when BXM was administrated after symptom onset at Day 2 p.i. compared with vehicle and OSP, although body temperature changes largely overlapped between Day 2 and Day 4. Conclusions The results highlight the rapid antiviral action of BXM with post‐exposure prophylaxis or therapeutic dosing in ferrets and offer support for further research on prevention of influenza virus infection and transmission.
- 13 June 2020
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (6) , 710-719
Open AccessThe antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
Background Baloxavir marboxil (BXM), the oral prodrug of baloxavir acid (BXA), greatly reduces virus titers as well as influenza symptoms of uncomplicated influenza in patients. Objectives To investigate the pharmacokinetic profiles of BXA and its efficacy against influenza A virus infection in ferrets. Methods Ferrets were dosed orally with BXM (10 and 30 mg/kg twice daily for 1 day), oseltamivir phosphate (OSP) (5 mg/kg twice daily for 2 days) or vehicle to measure the antiviral effects of BXM and OSP. The pharmacokinetic parameters of BXA was determined after single oral dosing of BXM. Results The maximum plasma concentrations of BXA were observed at 1.50 and 2.00 hours with the two BXM doses, which then declined with an elimination half‐life of 6.91 and 4.44 hours, respectively. BXM at both doses remained detectable in the plasma in ferrets, which may be due to higher stability in liver microsomes. BXM (10 and 30 mg/kg twice daily) treatment at Day 1 post‐infection (p.i.) reduced virus titers by ≥3 log10 of the 50% tissue culture infective doses by Day 2, which was significantly different compared with vehicle or OSP. Body temperature drops over time were significantly greater with BXM than with vehicle or OSP. Significant reduction in virus titers was also demonstrated when BXM was administrated after symptom onset at Day 2 p.i. compared with vehicle and OSP, although body temperature changes largely overlapped between Day 2 and Day 4. Conclusions The results highlight the rapid antiviral action of BXM with post‐exposure prophylaxis or therapeutic dosing in ferrets and offer support for further research on prevention of influenza virus infection and transmission.
- Open Access
- 1 February 2019
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 368 (2) , 157-168
Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance
In vitro-in vivo extrapolation (IVIVE) of renal excretory clearance (CLR) using the physiologically-based kidney models can provide mechanistic insight into the interplay of multiple processes occurring in the renal tubule. However, the ability of these models to quantitatively capture the impact of perturbed conditions (e.g., urine flow/ urine pH changes) on CLR has not been fully evaluated. The current work aimed to assess the predictability of the effect of urine flow and urine pH on CLR and tubular drug concentrations (selected examples). Passive diffusion clearance across the nephron tubule membrane was scaled from in vitro Caco-2 permeability data by nephron tubular surface area to predict fraction reabsorbed and CLR of caffeine, chloramphenicol, creatinine, dextroamphetamine, nicotine, sulfamethoxazole and theophylline. CLR values predicted using mechanistic kidney model at urinary pH of 6.2 and 7.4 resulted in prediction bias of 2.87 and 3.62-fold, respectively. Model simulations captured urine flow dependent CLR, albeit with minor under-prediction of the observed magnitude of change. The relationship between drug solubility, urine flow and urine pH, illustrated in simulated intra-tubular concentrations of acyclovir and sulfamethoxazole, was in agreement with clinical data on tubular precipitation and crystal-induced acute kidney injury. This study represents the first systematic evaluation of the ability of the mechanistic kidney model to capture the impact of urine flow and urine pH on CLR and drug tubular concentrations with the aim to facilitate refinement of IVIVE-based mechanistic prediction of renal excretion.
- 1 February 2019
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 368 (2) , 157-168
Open AccessTowards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance
In vitro-in vivo extrapolation (IVIVE) of renal excretory clearance (CLR) using the physiologically-based kidney models can provide mechanistic insight into the interplay of multiple processes occurring in the renal tubule. However, the ability of these models to quantitatively capture the impact of perturbed conditions (e.g., urine flow/ urine pH changes) on CLR has not been fully evaluated. The current work aimed to assess the predictability of the effect of urine flow and urine pH on CLR and tubular drug concentrations (selected examples). Passive diffusion clearance across the nephron tubule membrane was scaled from in vitro Caco-2 permeability data by nephron tubular surface area to predict fraction reabsorbed and CLR of caffeine, chloramphenicol, creatinine, dextroamphetamine, nicotine, sulfamethoxazole and theophylline. CLR values predicted using mechanistic kidney model at urinary pH of 6.2 and 7.4 resulted in prediction bias of 2.87 and 3.62-fold, respectively. Model simulations captured urine flow dependent CLR, albeit with minor under-prediction of the observed magnitude of change. The relationship between drug solubility, urine flow and urine pH, illustrated in simulated intra-tubular concentrations of acyclovir and sulfamethoxazole, was in agreement with clinical data on tubular precipitation and crystal-induced acute kidney injury. This study represents the first systematic evaluation of the ability of the mechanistic kidney model to capture the impact of urine flow and urine pH on CLR and drug tubular concentrations with the aim to facilitate refinement of IVIVE-based mechanistic prediction of renal excretion.
- 10 January 2018
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 107 (5) , 1443-1453
Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance
- 10 January 2018
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 107 (5) , 1443-1453
Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance
- Open Access
- 23 December 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e83146
Effects of Atrial Natriuretic Peptide on Bicarbonate Transport in Long- and Short-Looped Medullary Thick Ascending Limbs of Rats
Atrial natriuretic peptide (ANP) is known to influence NaCl transport in the medullary thick ascending limbs (MAL), where the largest NaCl reabsorption occurs among distal nephron segments in response to arginine vasopressin (AVP). In the present study, we investigated the effect of ANP on bicarbonate (HCO3−) transport in the MAL using an isolated tubule perfusion technique. The HCO3− concentration was measured using free-flow ultramicro-fluorometer. We first observed basal HCO3− reabsorption in both long- and short-looped MALs (lMALs, and sMALs, respectively). AVP inhibited HCO3− reabsorption in both lMALs and sMALs, whereas ANP did not change HCO3− transport. However, in the presence of AVP, ANP restored the HCO3− reabsorption inhibited by AVP both in lMAL and sMAL. The effects of ANP on HCO3− transport was mimicked by cyclic GMP. The mRNA expression level of the vasopressin V2 receptor in lMALs was significantly higher than in sMALs, whereas expression of the V1a receptor was unchanged. In summary, AVP inhibits HCO3− transport, and ANP counteracts the action of AVP on HCO3− transport both in lMALs and sMALs.
- 23 December 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e83146
Open AccessEffects of Atrial Natriuretic Peptide on Bicarbonate Transport in Long- and Short-Looped Medullary Thick Ascending Limbs of Rats
Atrial natriuretic peptide (ANP) is known to influence NaCl transport in the medullary thick ascending limbs (MAL), where the largest NaCl reabsorption occurs among distal nephron segments in response to arginine vasopressin (AVP). In the present study, we investigated the effect of ANP on bicarbonate (HCO3−) transport in the MAL using an isolated tubule perfusion technique. The HCO3− concentration was measured using free-flow ultramicro-fluorometer. We first observed basal HCO3− reabsorption in both long- and short-looped MALs (lMALs, and sMALs, respectively). AVP inhibited HCO3− reabsorption in both lMALs and sMALs, whereas ANP did not change HCO3− transport. However, in the presence of AVP, ANP restored the HCO3− reabsorption inhibited by AVP both in lMAL and sMAL. The effects of ANP on HCO3− transport was mimicked by cyclic GMP. The mRNA expression level of the vasopressin V2 receptor in lMALs was significantly higher than in sMALs, whereas expression of the V1a receptor was unchanged. In summary, AVP inhibits HCO3− transport, and ANP counteracts the action of AVP on HCO3− transport both in lMALs and sMALs.